An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.

Also called NCT01151410

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 208 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01151410
  • EudraCT 2009-017029-20
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Guatemala, Hungary, Poland, Puerto Rico, Slovakia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01151410. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2016-03-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Condition
Hypertension
Intervention (Drug)
Aliskiren
Intervention (Drug)
Enalapril
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01151410
Content hash
3ed130a527fa7bf436109c17c649cc027e02730ed844b15c1299e06d36f006b0